<DOC>
	<DOCNO>NCT00002775</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine docetaxel estramustine treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Docetaxel Plus Estramustine Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , toxicity , pharmacokinetic profile docetaxel combination estramustine patient metastatic adenocarcinoma prostate . II . Determine safe dose level regimen Phase II evaluation . III . Determine efficacy regimen evaluation objective response rate , duration response , time disease progression patient . IV . Determine duration survival patient regimen . V. Evaluate symptomatic quality life effect patient . OUTLINE : This dose escalation study ( phase I ) . Patients stratify one two risk group number prior chemotherapy regimen ( 0-2 v great 2 ) occurrence site ( ) prior radiation . Patients receive oral estramustine three time daily begin 24 hour prior docetaxel continue 4 day infusion . Patients receive docetaxel IV 1 hour every 21 day . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) reach ( phase I ) . The MTD define dose precede 2 6 patient experience dose limit toxicity . A minimum 6 patient receive treatment MTD . Phase II : Patients receive docetaxel IV MTD phase I . Treatment continue absence disease progression unacceptable toxicity phase . Quality life assess . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 12-37 patient accrue study within 13-19 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma prostate Failure androgen ablation ( orchiectomy luteinizing hormone release hormone , flutamide ) Rise PSA great 50 % nadir confirm 2 measurement 1 week apart Appearance new soft tissue lesion Appearance new lesion bone scan Measurable evaluable disease No symptomatic ascites , pleural effusion , peripheral edema great trace No brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No history coagulopathy Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 2.0 time ULN Alkaline phosphatase great 5.0 time ULN Renal : Creatinine great 2.0 time ULN Cardiovascular : No myocardial infarction within past 6 month Pulmonary : No prior pulmonary embolus Neurologic : No prior cerebrovascular accident No symptomatic peripheral neuropathy great grade 1 No significant neurologic psychiatric disorder ( psychotic disorder , dementia , seizure ) Other : No prior malignancy within past 5 year , except : Excised curatively irradiate nonmelanomatous skin cancer No serious illness medical condition No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy At least 6 week since prior isotope therapy No prior radiotherapy great 30 % bone marrow Surgery : Not specify Other : At least 4 week since prior investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>